Apotea AB Receivables

Apotea AB (APOTEA.ST) currently reports a receivables of $500M as of June 2026. That compares with $430M in the prior-year period — up 18.3% year over year. Use the charts on this page to explore Apotea AB's receivables history and peer comparisons.

Apotea AB's receivables increased from $430M to $500M — a 18.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apotea AB reported $500M in receivables as of June 2026. That compares with $430M in the prior-year period — up 18.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $500M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apotea AB, and consider following APOTEA.ST for alerts when major investors trade the stock.